ClinicalTrials.gg
RecruitingNCT06441630Updated Feb 4, 2025

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A Phase 3 interventional study of AD-227A and AD-227B in Essential Hypertension, sponsored by Addpharma Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.

Started
2024
with 3 others
Phase 3
5 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is one of 4 that started in 2024, is one of 5 in phase 3, and was the 8th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Essential Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Read the detailed description

Essential Hypertension

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Patients with Essential Hypertension
  • Other inclusions applied

Exclusion criteria

Exclusion Criteria:

  • Patient with Secondary Hypertension
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
251 participants (estimated)

Study arms

  • Experimental
    Co-administration of AD-227A and AD-227B

    AD-227A + AD-227B + Placebo of AD-227C

    Drug: AD-227A · Drug: AD-227B · Drug: Placebo of AD-227C

  • Active comparator
    AD-227A

    AD-227A + Placebo of AD-227B + Placebo of AD-227C

    Drug: AD-227A · Drug: Placebo of AD-227B · Drug: Placebo of AD-227C

  • Active comparator
    Co-administration of AD-227A and AD-227C

    AD-227A + Placebo of AD-227B + AD-227C

    Drug: AD-227A · Drug: AD-227C · Drug: Placebo of AD-227B

Interventions

  • DrugAD-227A

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • DrugAD-227B

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • DrugAD-227C

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • DrugPlacebo of AD-227B

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • DrugPlacebo of AD-227C

    Per Oral, 1 Tablet, Once a day for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change in MSSBP

    Change from Baseline in Mean Sitting Systolic Blood Pressure

    Time frame: Baseline to Week8

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2025, 14 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 14 months is below that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06441630
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 31, 2024
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Feb 4, 2025

Study contacts

JeongEun Park
Contact
parkje@addpharma.co.kr
+82-31-891-6989
Chong-Jin Kim
principal investigator · Gangnam CHA Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion